Determinants of selection into buprenorphine/naloxone among people initiating opioid agonist treatment in British Columbia.
F Homayra, N Hongdilokkul, M Piske, LA Pearce, H Zhou, JE Min, E Krebs, B Nosyk
Drug Alcohol Depend | Published : 2020
BACKGROUND: Studies assessing the comparative effectiveness of methadone versus buprenorphine/naloxone for opioid use disorder in real-world settings are rare - challenged by structural differences in delivery across settings and factors influencing treatment selection. We identified determinants of selection into buprenorphine/naloxone and quantified contributions of individual and provider-level covariates in a setting delivering both medications within the same healthcare settings. METHODS: Utilizing linked health administrative datasets, we conducted a retrospective cohort study of people with opioid use disorder (PWOUD) receiving opioid agonist treatment (OAT) in British Columbia, Canad..View full abstract
Awarded by Health Canada Substance Use and Addictions Program